Has the stockmarket bounce stalled?
US stocks have come under renewed pressure as America suffers a second wave of Covid infections.

Is the “bear market rally” over? America’s S&P 500 index finished last week 6.9% off its 8 June high, says Chuck Jones on Forbes. The problem is a surging coronavirus epidemic in the southern states, with new cases across Texas, Arizona and Florida more than quadrupling since the start of June. Add in “very high” equity valuations and it is difficult to see how this rally continues.
The FTSE underperforms
America’s Covid-19 failures are now difficult to ignore, says John Authers on Bloomberg. Mobility data in affected states is sagging again even as levels in much of Europe return to normal. Hotel, cruise and airline stocks have come under renewed pressure.
Talk of a “trade-off” between fighting the coronavirus and saving the economy has proved a false choice. If Covid-19 is rampant then consumers will choose to stay home, preventing the economy from functioning normally.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
On this side of the Atlantic, markets have probably learnt to live with the idea that there will be “occasional flare-ups” in cases, says Jim Armitage for the Evening Standard. Yet the FTSE still finished the second quarter on a gloomy note following news that UK GDP fell at its fastest pace in 41 years in the first quarter.
The FTSE 100 finished the second quarter this week up 9%, its best return in a decade. Yet it remains down 18% for the year as a whole, significantly worse than the 5% fall on the S&P 500 or the 8% decline on Japan’s Topix and Germany’s Dax indices. The London market remains a “serial underperformer” compared with other major markets, says Michael Hewson of CMC Markets.
The easy money has been made
There is an argument that US stocks are actually cheaper than they should be, says James Mackintosh in The Wall Street Journal. Near-zero interest rates are locked in for the foreseeable future and Treasury bond yields are “on the floor”, so their yields will not tempt equity investors.
With money so cheap, financial models imply that stock valuations should be high. Savers, after all, have few other places to earn a decent return. Yet vertiginous valuations are starting to induce “altitude sickness” in some investors, says Edward Bonham-Carter of Jupiter Asset Management. The resurgence in US coronavirus cases will keep stock markets under pressure for now, reckons Oliver Jones for Capital Economics. Yet we are far from bubble territory. One reason that valuations look so high is because analysts have slashed earnings forecasts for this year, but profits should rebound once the pandemic is behind us. Equities are poised to outperform, just so long as runaway virus outbreaks don’t force any major economies back into lockdown again.
Talk that much higher earnings are just around the corner sounds like bubble logic, says Randall Forsyth in Barron’s. Globally, stocks have just had one of their best quarters in decades. Markets are not necessarily heading for a crash, but it seems the “easy money has been made… caution should be the byword”.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Lloyds axes foreign currency fees for Club Lloyds customers
Club Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
By Daniel Hilton Published
-
How to invest during stagflation
Trump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
By Dan McEvoy Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine Published
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves Published